Hypertrophic cardiomyopathy (HCM) is a prevalent inherited cardiac disease (≈1:200) marked by left-ventricular hypertrophy and most commonly driven by pathogenic variants in sarcomeric genes, including cardiac troponin I (TNNI3). In addition to cardiomyocyte dysfunction, HCM is frequently accompanied by myocardial fi...
W. Seddiq, Y. Psaras, J. Chan et al.· European Heart Journal· 0 citations
The mechanisms and current uses of gene upregulation strategies are reviewed and their advantages and limitations are critically evaluated as therapies for inherited cardiomyopathies.
Rosemary B. Kirk, C. Santiago, Hugh Watkins et al.· Nature Cardiovascular Resear...· 0 citations
Findings indicate that uORF-mediated repression of TTN is context-dependent and not recapitulated in a disease-relevant model, which highlights the complex regulation of TTN expression and the importance of validating regulatory elements in their endogenous context.
Rosemary B. Kirk, Alexander J. Sparrow, Marta Moya-Jódar et al.· Molecular Therapy: Nucleic A...· 1 citation
SVIL-associated cardiomyopathy is established as a mechanistically distinct form of HCM and drugs targeting mitochondrial bioenergetics may be a therapeutic strategy in patients with SVIL-associated cardiomyopathy.
Yifan J. Li, Y. Psaras, V. Steeples et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.